Eagle Pharmaceuticals Granted Unique J-Code and Pass-Through Status for BARHEMSYS® from CMS
-- J-code is effective January 1, 2024, and transitional pass-through status became effective October 1, 2023, facilitating patient access -- -- BARHEMSYS is the first and only antiemetic approved by the FDA for rescue treatment…